Cbdmd INc (YCBD) has disclosed a new risk, in the Accounting & Financial Operations category.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
CbdMD Inc. faces a critical juncture as it grapples with a continuation of negative growth rates. The company’s revenue has significantly declined over the past two fiscal years, with a 32% decrease to $24.2 million in 2023. This downturn reflects challenges such as changing social media algorithms, regulatory pressures, and a highly competitive market. Despite efforts to curtail expenses and optimize cash flow, persistent operational difficulties and the necessity for strategic adaptation raise concerns about the company’s future performance.
Overall, Wall Street has a Moderate Buy consensus rating on YCBD stock based on 1 Buy.
To learn more about Cbdmd INc’s risk factors, click here.
